The KRAS-variant is one of the first discovered members of a new class of genetic markers that predict increased cancer risk and unique treatment response to cancer therapy. The biology of the KRAS-variant affords great promise for both preventing and curing cancer in individuals with this inherited mutation.

 

Radiogenomics 

Currently, there are no biomarkers applied before radiation therapy treatment to identify patients who have different sensitivities to radiation therapy.  As this treatment is used in over 67% of cancer patients there is a strong need to make strides towards personalizing radiotherapy.  MiraDx is developing a panel of such biomarkers, using their novel, proprietary germ-line, functional biomarkers, such as the KRAS-variant.

Personalized Medicine

The KRAS-variant is a biomarker that alone has been shown to significantly predict sensitivity and resistance to specific cancer treatments, regardless of tumor type.  This information can subgroup patients into responders or non-responders to therapies being used today. In addition, recent work has shown that the KRAS-variant is a strong biomarker of baseline immune status and inflammatory response.  This has led us to apply the KRAS-variant and a panel of biomarkers like it to developing immunotherapies.  Currently work is ongoing to develop the best approaches to treat cancer patients with the KRAS-variant, as well as with other mutations in its class.  Application of this class of biomarkers is a significant leap forward in personalizing cancer therapy.

The KRAS-variant and Women’s Health

As shown in numerous independent studies, women with the KRAS-variant are at an increased risk of developing breast and ovarian cancer, non-small cell lung cancer, and multiple primary breast cancer.  Recent data now indicates that changing estrogen levels, specifically estrogen withdrawal, can trigger cancer in women with the KRAS-variant.  Knowing a woman’s KRAS-variant status is an additional piece of critically important information to help direct decisions for estrogen management, as well as primary and secondary cancer screening.

AT testing

MiraDx has a program to confirm a diagnosis of  Ataxia Telangiectasia in children, based on work from the Gatti laboratory spanning over 40 years.

FROM THE DECEMBER 2014 ISSUE

discover-mag

The Little-Known Genetic Mutation Behind Many Aggressive Cancers

Despite the dangers of the KRAS-variant mutation, few doctors have heard of it. But one researcher is trying to change that.

Read more

Are you interested in ongoing studies about the KRAS-variant?

Visit our sister non-profit Mirakind, and register for their newsletter to receive updates.